Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating income | -$727K | -$6.15M | -$18.6M | -$19.4M | -$15.7M | -$28.0M |
| Net income | -$2.34M | -$6.84M | -$17.6M | -$18.5M | -$16.8M | -$34.7M |
| EPS (diluted) | -$0.51 | -$0.81 | -$1,082.79 | -$3,419.01 | -$1,336.63 | -$52.59 |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$493K | -$5.27M | -$15.8M | -$18.1M | -$13.3M | -$19.5M |
| Capital expenditures | — | $255K | $101K | $35.6K | $21.8K | $6.66K |
| Free cash flow | — | -$5.52M | -$15.9M | -$18.1M | -$13.4M | -$19.5M |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $828K | $20.8M | $4.97M | $2.77M | $5.81M | $17.8M |
| Total assets | $1.06M | $22.9M | $7.59M | $5.17M | $7.29M | $162M |
| Total liabilities | $4.46M | $2.53M | $4.35M | $3.53M | $9.31M | $10.5M |
| Shareholders' equity | -$3.41M | $20.4M | $3.24M | $1.64M | -$2.02M | $10.3M |
| Retained earnings | -$3.46M | -$10.3M | -$27.9M | -$46.4M | -$63.2M | -$97.9M |
| Shares (wtd avg diluted) | 4.64M | 8.43M | 16.2B | 5.42B | 12.6B | 690K |
Every figure is extracted from Transcode Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.